Liquidia (LQDA) Revenue & Revenue Breakdown
Liquidia Revenue Highlights
Latest Revenue (Y)
$17.49M
Latest Revenue (Q)
$4.45M
Main Segment (Y)
Promotion Agreement
Main Geography (Y)
Promotion Agreement
Liquidia Revenue by Period
Liquidia Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $17.49M | 9.75% |
2022-12-31 | $15.94M | 23.98% |
2021-12-31 | $12.85M | 1637.81% |
2020-12-31 | $739.63K | -90.84% |
2019-12-31 | $8.07M | 198.20% |
2018-12-31 | $2.71M | -62.70% |
2017-12-31 | $7.26M | -45.08% |
2016-12-31 | $13.22M | - |
Liquidia Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $4.45M | 21.56% |
2024-06-30 | $3.66M | 23.12% |
2024-03-31 | $2.97M | -34.41% |
2023-12-31 | $4.53M | 23.19% |
2023-09-30 | $3.68M | -23.15% |
2023-06-30 | $4.79M | 6.52% |
2023-03-31 | $4.49M | -16.18% |
2022-12-31 | $5.36M | 69.35% |
2022-09-30 | $3.17M | -19.22% |
2022-06-30 | $3.92M | 12.20% |
2022-03-31 | $3.49M | 8.62% |
2021-12-31 | $3.22M | 1.14% |
2021-09-30 | $3.18M | -5.85% |
2021-06-30 | $3.38M | 9.48% |
2021-03-31 | $3.08M | 316.92% |
2020-12-31 | $739.63K | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $-120.00 | 100.00% |
2019-09-30 | - | -100.00% |
2019-06-30 | $8.07M | 100.00% |
2019-03-31 | - | -100.00% |
2018-12-31 | $568.40K | 234.89% |
2018-09-30 | $169.73K | -83.72% |
2018-06-30 | $1.04M | 12.63% |
2018-03-31 | $925.97K | -49.01% |
2017-12-31 | $1.82M | -0.26% |
2017-09-30 | $1.82M | -8.13% |
2017-06-30 | $1.98M | 20.91% |
2017-03-31 | $1.64M | - |
Liquidia Revenue Breakdown
Liquidia Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 20 |
---|---|
Research and Development Services | - |
Promotion Agreement | $739.63K |
Latest
Quarterly Revenue by Product
Product/Service | Jun 19 | Dec 18 | Sep 18 | Jun 18 |
---|---|---|---|---|
Research And Development Services | $200.00 | $568.40K | $169.73K | $99.46K |
Collaboration And Licensing Milestones | $1.35M | $45.06K | $45.06K | - |
Collaboration And Licensing Non Refundable Upfront Payments | $6.73M | $1.17M | $943.42K | - |
Latest
Liquidia Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 20 | Dec 19 | Dec 18 |
---|---|---|---|
Promotion Agreement | $739.63K | - | - |
Research and Development Services | - | $200.00 | - |
Non-Refundable Payments - Milestones | - | $1.35M | - |
Non-Refundable Payments - Up-front Payments | - | $6.73M | - |
Collaboration And Licensing Milestones | - | - | $45.06K |
Collaboration And Licensing Non Refundable Upfront Payments | - | - | $1.17M |
Research And Development Services | - | - | $1.49M |
Latest
Quarterly Revenue by Country
Country | Jun 19 | Dec 18 | Sep 18 | Jun 18 |
---|---|---|---|---|
Research And Development Services | $200.00 | $568.40K | $169.73K | $99.46K |
Collaboration And Licensing Milestones | $1.35M | $45.06K | $45.06K | - |
Collaboration And Licensing Non Refundable Upfront Payments | $6.73M | $1.17M | $943.42K | - |
Latest
Liquidia Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
UTHR | United Therapeutics | $2.33B | $748.90M |
TECH | Bio-Techne | $1.16B | $289.46M |
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
LEGN | Legend Biotech | $285.14M | $93.99M |
IMCR | Immunocore | $249.43M | $75.40M |
MIRM | Mirum Pharmaceuticals | $186.37M | $77.88M |
AGEN | Agenus | $156.31M | $25.11M |
LQDA | Liquidia | $17.49M | $4.45M |
KRON | Kronos Bio | $6.29M | $2.37M |
LYRA | Lyra Therapeutics | $1.56M | $195.00K |
GERN | Geron | $237.00K | $28.21M |
XFOR | X4 Pharmaceuticals | - | $560.00K |
PCVX | Vaxcyte | - | - |
GOSS | Gossamer Bio | - | $9.48M |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
REPL | Replimune Group | - | - |
NRXP | NRx Pharmaceuticals | - | - |
TERN | Terns Pharmaceuticals | - | - |
LRMR | Larimar Therapeutics | - | - |
NVCT | Nuvectis Pharma | - | - |
KALV | KalVista Pharmaceuticals | - | - |